A Randomized, Open-Label Phase 1b Study of ME1100 Inhalation Solution Plus Best Available Therapy in the Treatment of Mechanically Ventilated Subjects With Bacterial Pneumonia
Phase of Trial: Phase I
Latest Information Update: 07 Jul 2017
At a glance
- Drugs Arbekacin (Primary)
- Indications Bacterial infections; Pneumonia
- Focus Pharmacokinetics
- Sponsors Meiji Seika Pharma
- 03 Jul 2017 Status changed from recruiting to completed.
- 01 Nov 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Mar 2017.
- 13 May 2016 Study design changed from double blind to open label study. Placebo arm removed from the treatment table hence number of treatment arms changed from 3 to 2.